Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Optimal application of PD-L1 IHC tests

Emina E. Torlakovic • 12 Apr 2021
AACR 2021
General

Emina E. Torlakovic, PhD, MD, FCAP, University of Saskatchewan, Saskatoon, Canada, discusses the optimal use of PD-L1 immunohistochemistry (IHC) tests, suggesting high value in the early stages of clinical trial design when biomarkers have not yet been defined. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

More from Emina E. Torlakovic

4:05
Analysis and comparison of PD-L1 IHC tests
Emina E. Torlakovic • 12 Apr 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals